22 results about "Human pathogen" patented technology

The invention discloses an application of Lactobacillus plantarum in at least one of the following items: a1, an application in improving the silage quality of silage, a2, an application in improving the silage quality, a3, an application in improving the silage quality, a4, an application in improving the silage quality, and a5, an application in improving the silage quality. A2, application in preparation of silage; a3, application in preparation of a silage additive; the strain name of the lactobacillus plantarum is LA2, the lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the lactobacillus plantarum is CGMCC No. 33484. According to the invention, the lactobacillus plantarum or the microbial inoculum thereof or the silage additive thereof is added into the silage for the first time, and tetracycline resistance genes in the silage can be remarkably reduced; after the lactobacillus plantarum or the microbial inoculum thereof or the silage additive thereof disclosed by the invention is added, the generation and residue of tetracycline resistance genes in feed can be reduced, the propagation of the tetracycline resistance genes in a food chain is reduced, the safety of forage grass is ensured, and the damage to animals, environment and human bodies is reduced; and the drug resistance of human pathogenic bacteria is reduced while the health level of animals is improved.

The invention discloses a pathogenic bacterium infection prevention and treatment krill NC-K143, a bacteriostatic agent and application of the pathogenic bacterium infection prevention and treatment krill NC-K143 and the bacteriostatic agent. According to the present invention, the classification name of the Leptospora sp. NC-K143 is Kitasatospora sp.NC-K143, the strain has been preserved in the China Center for Type Culture Collection on March 27, 2025, and the preservation number is CCTCC NO: M 2025616. The invention further provides the application of the Leptospora sp. NC-K143, and the Leptospora sp. NC-K143 and the application of the Leptospora sp. NC-K143, according to the present invention, the Leptospora kurtosis NC-K143 provides inhibition effects for a variety of bacteria and yeast-like fungi, and particularly provides the best inhibition effects for gram-positive bacteria, such as staphylococcus aureus; the krill NC-K143 disclosed by the invention can be used for preparing a medicine for preventing and treating pathogenic bacteria infection of a human body, and has important significance on reducing the use of a large amount of antibiotics, reducing environmental pollution and reducing the generation of drug-resistant bacteria.

The present invention provides a method for treating crops in field or in a processing facility comprising the steps of producing a dry composition comprising a metabisulphite, a benzoate salt and a cellulose additive; preparing said dry composition as a formulation; and applying the formulation to a crop, wherein said treatment is for prevention or reduction of crop damage by plant pathogens, or reduction of bacterial, fungal or human pathogens.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

A system includes a processor and a non-transitory computer readable medium that stores executable instructions for determining an expected potency of a drug in treating a human pathogen. The executable instructions include a sampler interface that receives sequence data representing the human pathogen and generates a dataset comprising one of raw nucleic acid sequence data, ribonucleic acid sequence data, or amino acid sequence data. A pathogen characterizer generates a representation of the human pathogen from the dataset. A potency analyzer receives the representation of the human pathogen from the pathogen characterizer and a representation of the drug and outputs a value representing a potency of the drug as applied to the human pathogen. The potency analyzer can be used with a pathogen simulator that generates a representation of a pathogen and a drug simulator that generates a representation of a drug to iteratively discover new pathogens and drugs.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mll2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modelled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic dells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

The present invention belongs to the field of antimicrobial peptides, and specifically relates to an antimicrobial peptide, antimicrobial product and application that inhibits a variety of human pathogens. The antimicrobial peptide is named CAMP1229NC, and is obtained by capping the polypeptide shown in SEQ ID NO:1 with an N-terminal acetyl group and a C-terminal amino group. The antimicrobial peptide exhibits significant antibacterial activity against Staphylococcus aureus standard strain ATCC12600, Pseudomonas aeruginosa PAO1, Klebsiella pneumoniae, Acinetobacter baumannii standard strain ATCC19606, methicillin-resistant Staphylococcus aureus ATCC33591, methicillin- and gentamicin-resistant Staphylococcus aureus ATCC33592 and Acinetobacter baumannii bio-53272 resistant to multiple antibiotics, effectively overcoming the limitations of traditional antimicrobial peptides.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

Crimean-Congo hemorrhagic fever virus (CCHFV) is an important human pathogen. Limited evidence suggests that antibodies can protect humans against lethal CCHFV disease, but the protective efficacy of antibodies has never been evaluated in adult animal models. Here adult mice were used to investigate the protection provided by glycoprotein-targeting neutralizing and non-neutralizing monoclonal antibodies (mAbs) against CCHFV infection. A single non-neutralizing antibody (mAb-13G8) was identified that protected adult type I interferon deficient mice >90% when treatment was initiated prior to virus exposure and >60% when administered after virus exposure. Neutralizing antibodies known to protect neonatal mice from lethal CCHFV infection, failed to confer protection regardless of IgG subclass. The target of mAb-13G8 was identified as GP38, one of multiple proteolytically-cleaved glycoproteins derived from the CCHFV glycoprotein precursor polyprotein. Robust protection required complement activity, but not Fc-receptor functionality. Consistently, it was found that GP38 previously identified as a secreted molecule also localizes to viral envelope and cellular plasma membranes. This study reveals GP38 as an important antibody target for CCHFV and lays the foundation to develop novel vaccines and immunotherapeutic against CCHFV in human.

Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and / or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of drugs for preventing and / or treating tumors. The HPK1 inhibitor is a compound represented by following general formula I, or pharmaceutically acceptable salts, stereoisomers, esters, prodrugs, solvates and deuterated compounds thereof.

The application discloses a primer probe combination for detecting a novel human circovirus, a kit and application thereof, and belongs to the technical field of biotechnology. In view of defects that existing detection methods of the novel human circovirus rely on metagenomic sequencing, are time-consuming, high in cost and difficult to realize accurate quantification, the application designs specific primers and TaqMan probes with fluorescent labels based on a conservative region of a replicase protein gene of the novel human circovirus, and the specific primers and the TaqMan probes have no cross reaction with other viruses of the circovirus genus (including porcine circovirus types 1-4 and the like) and other common human pathogens, and high-specificity detection can be realized. The kit comprises the primer probe combination, PCR reaction components, positive and negative quality control samples and quantitative standard samples, and has the advantages of simple operation, high sensitivity and high amplification efficiency, and provides an effective means for rapid and accurate quantification detection of the novel human circovirus, and can be applied to the fields of clinical sample detection, blood screening and epidemiological monitoring.

The present invention is directed to methods and devices for identification of pathogens, and more particularly to solid phase recombinase polymerase amplification (SP-RPA) methods and devices for massively multiplexed solid-phase isothermal identification of human pathogens from patient samples. The principal application for multiplexed solid-phase isothermal identification of human pathogens is point-of-care diagnostics.

The invention relates to the technical field of buffer solutions, and discloses a chemiluminescence probe conditioning buffer solution and a preparation method thereof, the chemiluminescence probe conditioning buffer solution comprises the following raw materials by mass: 5%-10% of animal serum, 0.1%-0.5% of a chelating agent, 0.8%-1.5% of an electrolyte, 0.05%-0.2% of a preservative, 0.02%-0.1% of a surfactant, and the balance deionized water; the animal serum is one of inactivated bovine serum, sheep serum or rabbit serum and is used for replacing human plasma to reduce the risk of biological exposure, the chelating agent is citrate or an aminocarboxylic acid compound, the electrolyte is chloride of alkali metal or alkaline earth metal, and the preservative is one of isothiazolinone, saccharide or azide. The animal serum is used for replacing traditional human plasma to serve as a core component, the biological exposure risk caused by non-thorough inactivation of human-derived pathogens is thoroughly avoided from the raw material source, the use safety of the product is remarkably improved, and the core potential safety hazard of an existing product is solved.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide for inhibiting various human pathogenic bacteria, an antibacterial product and application. The antibacterial peptide is named as CAMP1229NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention belongs to the technical field of biology, and particularly relates to a scrota-derived antibacterial peptide and application thereof. The antibacterial peptide from the scrota is SPC-1 or SPC-2, and the antibacterial peptide from the scrota is SPC-2; wherein the amino acid sequence of the SPC-1 is as shown in a sequence table SEQ ID NO. 1, and the amino acid sequence of the SPC-2 is as shown in a sequence table SEQ ID NO. 2. The scrota antibacterial peptide provided by the invention is novel in amino acid sequence, has remarkable antibacterial activity on gram-negative bacteria and gram-positive bacteria, shows broad-spectrum antibacterial property, and has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and by virtue of the characteristics, the scrota antibacterial peptide shows excellent antibacterial value; and a new resource is provided for the development of antibacterial products against the human pathogenic bacteria.

The invention discloses application of kaolin to reduction of antibiotic resistance propagation risk of compost products, only kaolin is added into livestock and poultry manure compost fermentation raw materials for aerobic composting, and the expression abundance of ARGs and MGEs in the compost products is reduced based on the unique antibacterial activity of kaolin to human pathogenic bacteria.

The present invention belongs to the field of biomedicine, and more specifically, to antimicrobial peptides that inhibit Staphylococcus aureus and Pseudomonas aeruginosa and their applications. The antimicrobial peptide CAMP648NC is a new type of cationic antimicrobial peptide with minimum inhibitory concentrations of 16 μg / mL and 32 μg / mL for pathogenic bacteria Staphylococcus aureus and Pseudomonas aeruginosa, respectively. It has extremely low cytotoxicity, and human skin keratinocytes HaCat and bronchial epithelial cells BEAS‑2B still maintain survival rates of 110.4% and 87.3% after being treated with the antimicrobial peptide CAMP648NC at a concentration of 128 μg / mL for 24 hours. These characteristics make it exhibit extremely high antimicrobial value as a medical drug, providing alternative medicinal resources for future clinical use against these two human pathogens.

The invention discloses application of lactobacillus plantarum in at least one of the following aspects: a1, application in improving silage quality of silage; a2, application in preparation of silage; a3, application in preparation of a silage additive; the strain name of the lactobacillus plantarum is LB1, the lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the lactobacillus plantarum is CGMCC NO.33485. The lactobacillus plantarum disclosed by the invention has the beneficial effects that the lactobacillus plantarum can be used for preparing the lactobacillus plantarum; the lactobacillus plantarum which is high in acid yield and capable of reducing the content / abundance of the sulfonamide antibiotic resistance genes is separated for the first time, and after the lactobacillus plantarum or the microbial inoculum or the silage additive of the lactobacillus plantarum is added, generation and residues of the sulfonamide antibiotic resistance genes in feed can be reduced; the spreading of sulfonamide antibiotic resistance genes in a food chain is reduced, the damage to animals, the environment and human bodies is reduced, the safety of forage grass is ensured, and the drug resistance of human pathogenic bacteria is reduced while the health level of the animals is improved.

Genetically modified non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and / or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and / or NK cells, and in various in vivo screens.

The present invention relates to pure cultures of strains of the family Lactobacillaceae or of the genus Bifidobacterium as well as next-generation probiotic for use as antimicrobials for inhibiting growth of a bacterium, such as infectious bacteria or a bacterium under infections conditions. Furthermore, the present invention relates to a substance or composition comprising such substantially pure cultures of strains of the family Lactobacillaceae or of the genus Bifidobacterium or of a next-generation probiotic, as well as to methods of treating a bacterial infection in mammals by administering such strains of the family Lactobacillaceae or of the genus Bifidobacterium or of a next-generation probiotic.